Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	9.70B
Revenue (ttm)	16.21B
Net Income (ttm)	665.03M
Shares Out	2.52B
EPS (ttm)	0.26
PE Ratio	14.76
Forward PE	13.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,289,900
Average Volume	65,418,977
Open	3.830
Previous Close	3.790
Day's Range	3.810 - 3.870
52-Week Range	2.540 - 4.970
Beta	0.19
RSI	62.69
Earnings Date	Apr 26, 2025

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2024, SHA:600664's revenue was 16.18 billion, an increase of 4.65% compared to the previous year's 15.46 billion. Earnings were 628.85 million, an increase of 59.10%.